O-1A Guide
O-1A Judging Criterion: A biotech CEO's Guide for September 2025
This guide covers the latest strategies and evidence requirements. Learn what changed and how to position your case.
The judging criterion and what is at stake for biotech executives
The judging criterion under 8 C.F.R. § 214.2(o)(3)(ii)(C) requires that the O-1A petitioner demonstrate participation as a judge of the work of others in the same or an allied field of specialization. For biotech CEOs and senior biotechnology executives, this criterion is among the most naturally available in the O-1A framework: the typical career trajectory of a senior biotech executive involves recurring invitations to evaluate the work of others — peer review of scientific manuscripts, grant application review for national research funding agencies, scientific advisory committee service, and evaluation of investment presentations from early-stage biotechnology companies. The challenge is not finding qualifying judging activity but documenting it with the specificity that USCIS requires to credit it as satisfying the criterion.
The judging criterion is one of eight O-1A criteria, of which a petitioner must satisfy at least three, or alternatively demonstrate receipt of a major internationally recognized award. For biotech CEOs who may lack strong evidence for the prizes criterion — because executive achievement in biotechnology does not map onto the Nobel Prize, Fields Medal, or equivalent award categories — or for the memberships criterion — because some executive roles do not involve selective professional association membership — the judging criterion often provides one of the more achievable of the required three. Practitioners building O-1A petitions for biotech executives should assess the judging criterion early in the evidence-mapping process and identify all qualifying judging engagements in the petitioner's career history before finalizing the criterion count.
What is at stake in getting the judging criterion documentation right is significant. A petition that claims the judging criterion but fails to provide adequately specific documentation is likely to receive an RFE requesting additional evidence — documentation that may or may not be available in adequate form at the time of the RFE. A petition that claims three criteria, one of which is inadequately documented, is a petition that effectively has only two clearly established criteria, which falls below the regulatory threshold. Practitioners should treat the judging criterion as requiring the same documentation rigor as any other criterion — not as a soft or easily established element of the petition — and should assemble the criterion documentation proactively before filing rather than hoping that a general description of peer review service will suffice.
Regulation requirements: what qualifies as judging service
The regulatory text of 8 C.F.R. § 214.2(o)(3)(ii)(C) is relatively broad: it requires that the petitioner have 'participated, either individually or on a panel, as a judge of the work of others in the same or an allied field of specialization.' USCIS Policy Manual guidance on the judging criterion confirms that the adjudicator should look for documented participation in a role that involved evaluating the work of others — not merely advising, mentoring, or supervising. The key distinguishing feature is evaluation: the judge makes or contributes to a determination about the quality, merit, or significance of another person's work in the field. Peer review of manuscripts submitted for scientific publication satisfies this definition because the reviewer evaluates the manuscript's scientific merit and makes a recommendation about publication. Service on a thesis committee may or may not satisfy the definition depending on whether the committee member's role involved evaluating the completed research rather than only supervising its conduct.
The requirement that the judging occur in 'the same or an allied field of specialization' is broadly interpreted. For a biotech CEO whose field of specialization is defined by their biotechnology expertise — molecular biology, oncology, computational drug discovery, or another specific domain — judging service in adjacent fields of biomedical research, translational science, or pharmaceutical development qualifies as allied field judging. USCIS does not require that every judging engagement be in the exact narrow specialty of the petitioner; it requires that the field of the work being judged bear a genuine relationship to the petitioner's field of extraordinary ability. Biotech CEOs who have served on grant review panels for the National Science Foundation covering computational biology, on advisory boards for medical device companies in related therapeutic areas, or on editorial boards for clinical medicine journals that publish translational research have facts supporting judging in allied fields.
The form of judging service that satisfies the criterion extends beyond traditional peer review to include: service on NIH Study Sections or Special Emphasis Panels as an ad hoc or standing member; service on NSF, DARPA, or BARDA grant review panels; service on the scientific advisory board of a foundation or government agency with responsibility for evaluating grant proposals or research programs; participation as a judge in recognized biotechnology startup pitch competitions where the evaluation criteria include scientific merit; and service on the scientific review committee of a recognized biotechnology conference with selective abstract review. Each of these forms of judging service involves the evaluation of others' work in the field, and each generates documentation — invitation letters, confirmation of participation, panel membership records — that can support the criterion.
Evidence that satisfies the judging criterion for biotech executives
The documentary foundation for the judging criterion in biotech executive O-1A petitions should include, for each judging engagement claimed: the invitation letter from the organizing institution identifying the petitioner by name and role, confirmation that the petitioner participated in the evaluation — attendance records, panelist lists, or correspondence confirming participation — and where available, a description of the evaluation process that identifies the criteria applied and the petitioner's role in the evaluation. Invitation letters from the National Institutes of Health confirming the petitioner's service as an ad hoc reviewer for a specific study section, NIH standing panel membership certificates, or NSF reviewer acknowledgment letters are the strongest forms of this documentation because they come from major nationally recognized research funding agencies with clearly established institutional standing.
For biotech executives who have served on the scientific advisory boards of recognized foundations, professional societies, or government agencies in an evaluation capacity, letters from the organization confirming the nature of the advisory board role — specifically, that the role involved review and evaluation of proposed or ongoing research programs rather than purely strategic advisory functions — are essential documentation supplements. Some scientific advisory board roles involve evaluation of grant proposals or research applications; others involve only strategic guidance on the organization's research agenda without evaluating specific applications. The distinction matters for criterion purposes: the former qualifies as judging in the regulatory sense, while the latter may not. Documentation should make this distinction clear.
Expert letters supporting the judging criterion should come from individuals who can attest to the significance of the specific judging roles the petitioner performed — the standing of the grant program, the selectivity of the review process, the quality of the panelists selected to serve, or the impact of the program's funding decisions on the field. A letter from a program officer at an NIH institute confirming that the petitioner served on a study section and explaining the study section's role in the NIH grant review process — including the selectivity of panelist selection and the volume of applications reviewed — provides expert context that USCIS adjudicators cannot supply from their own knowledge of the NIH peer review system. Similarly, a letter from the scientific director of a foundation grant program explaining the evaluation criteria and the petitioner's analytical role in the review process strengthens criterion documentation that might otherwise appear routine.
Evidence USCIS discounts for biotech judging claims
USCIS adjudicators applying heightened scrutiny to O-1A petitions for biotechnology executives consistently discount several categories of evidence that practitioners incorrectly treat as satisfying the judging criterion. First, supervising graduate students or postdoctoral fellows — even in a lab director or principal investigator role — does not constitute judging in the regulatory sense unless the supervision included formal evaluation of completed research for a degree committee or publication purpose. Mentorship and supervision are distinct from adjudicative evaluation; the regulatory criterion requires the latter. A biotech CEO who supervised a research team but did not serve on grant review panels, editorial boards, or selection committees for recognized programs has not satisfied the judging criterion through supervisory service alone.
Second, serving as a reference or endorser for grant applicants, job candidates, or award nominees does not satisfy the judging criterion. The criterion requires participation as a judge — a member of a panel or evaluation committee that makes or contributes to a selection decision — not participation as an advocate for a candidate's application. A biotech executive who writes letters of recommendation for colleagues applying for NIH grants, who endorses nominees for industry awards, or who provides professional references for job applicants has performed a supporting function in others' application processes, not a judging function in the regulatory sense. This distinction is important because executives' endorsement activities are often voluminous and may be cited in petitions as evidence of professional recognition; they do not satisfy the judging criterion regardless of volume.
Third, serving on the board of directors of a company in a fiduciary capacity — even a biotechnology company where the board makes strategic decisions about research programs — does not constitute judging of the work of others in the scientific field. Corporate board service involves governance decisions that may include approval or rejection of research programs, but the board member's role is a governance role rather than a peer review role. The distinction that USCIS draws is between evaluation of the scientific merit of work in the field — which satisfies the criterion — and governance, strategic, or investment decisions that may involve scientific programs as one input among many business considerations. Practitioners who present board service as judging evidence without clearly distinguishing it from peer scientific evaluation risk generating RFE activity around the criterion.
Borderline judging cases: framing ambiguous engagements
Biotech executives encounter several categories of judging engagement that fall in the borderline zone between clearly qualifying and clearly non-qualifying for the criterion. Scientific advisory board service is the most common borderline category: some SAB roles clearly involve evaluation of grant proposals or research applications (qualifying), while others involve only forward-looking strategic advice about research directions (non-qualifying). Petitioners with SAB experience should review the specific scope of their SAB responsibilities — ideally with documentation showing that the SAB reviewed specific research proposals, provided formal evaluations of specific programs, or made recommendation decisions on specific funding allocations — before claiming the engagement as judging evidence. An SAB role without this evaluative dimension does not satisfy the criterion, regardless of the board's prestige.
Investor diligence panels — where the biotech executive participates in evaluating investment presentations from early-stage companies seeking funding — present a similar borderline question. If the evaluation involves assessing the scientific merit of the company's technology against established standards in the field, with the executive providing expert opinion that influences the investment decision based on scientific quality, the engagement has characteristics of scientific judging. If the evaluation is primarily a business assessment of market opportunity, competitive positioning, and financial projections, the executive's role is an investment advisory function rather than a scientific judging function. Petitioners seeking to claim investor diligence service as judging evidence should develop documentation and expert letter support that specifically addresses the scientific evaluation component of the role and explains why it constitutes peer evaluation of scientific work rather than business advisory service.
Conference abstract review for scientific meetings presents a relatively clear case for criterion satisfaction when the conference has selective review standards and the petitioner's role involved evaluating submitted abstracts against scientific quality criteria. The American Society of Clinical Oncology annual meeting, the American Chemical Society national meetings, the BIO International Convention scientific programming, and similar recognized conferences select abstracts through review processes that involve expert evaluation of scientific merit. Biotech executives who have served on abstract review committees for these conferences have performed documented scientific evaluation that can satisfy the judging criterion — provided that the petition includes documentation of the committee's review function, the petitioner's specific participation, and the conference's standing in the relevant field. The documentation challenge is obtaining confirmation of specific participation from conference organizers, which requires outreach well in advance of the petition filing date.
Audit checklist: judging criterion for biotech CEO petitions
Before finalizing the judging criterion section of a biotech CEO O-1A petition, practitioners should verify the following for each judging engagement claimed. First: does the engagement involve evaluation of scientific work by the petitioner in a formal review role? Supervision, mentorship, endorsement, and board governance do not qualify. Second: is the organization conducting the review process a recognized entity in biotechnology or an allied scientific field? NIH, NSF, DARPA, BARDA, major scientific foundations, and recognized conference organizations with established review processes are typically recognized; informal or self-organized review groups are not. Third: can participation be documented with contemporaneous evidence? Invitation letters, panel membership confirmation, and where available, anonymized records of review participation should be obtainable for each claimed engagement.
Fourth: does each piece of documentation specifically identify the petitioner's role as evaluative rather than advisory or supervisory? Documentation that describes the petitioner as a 'scientific advisor' or 'board member' without specifying that the role involved evaluation of specific proposals, manuscripts, or applications may not clearly satisfy the criterion. Where role descriptions are ambiguous, expert letters from the organization's leadership — confirming the evaluative nature of the petitioner's participation — should accompany the documentary evidence. Fifth: has the field of the evaluated work been confirmed as the same as or allied to the petitioner's field of extraordinary ability? For biotech CEOs with narrow specializations, judging in allied fields requires a brief explanation of the relationship between the petitioner's specialty and the field of the work evaluated.
After confirming that each engagement satisfies the criterion, practitioners should assess whether the volume and quality of judging evidence is sufficient to establish the criterion clearly or merely arguably. A petition with one qualifying judging engagement documented with complete evidence satisfies the criterion but provides no margin for adjudicator skepticism. A petition with three or four qualifying judging engagements from distinct organizations — each documented with an invitation letter, participation confirmation, and expert context — establishes the criterion with a margin that withstands scrutiny more reliably. Biotech executives who discover through the audit that they have only one documented qualifying engagement should consider whether additional qualifying engagements can be identified and documented before filing, or whether the petition should be structured around a stronger combination of other criteria with judging as a supplementary showing.